Brix Biopharma Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 04-12-2024
- Paid Up Capital ₹ 0.10 M
as on 04-12-2024
- Company Age 5 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 7.60 Cr
as on 04-12-2024
- Revenue 495.97%
(FY 2022)
- Profit -22.66%
(FY 2022)
- Ebitda -11.41%
(FY 2022)
- Net Worth 80.41%
(FY 2022)
- Total Assets 40.15%
(FY 2022)
About Brix Biopharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹7.60 Cr.
Dipesh Shah, Kamlesh Jain, Atish Jain, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24230MH2019PTC332985
- Company No.
332985
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Nov 2019
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Brix Biopharma Private Limited offer?
Brix Biopharma Private Limited offers a wide range of products and services, including Anti Infective Drugs & Medicines, Antibacterial Drugs, Common Disease Medicines, Pharmaceutical Tablets, Nutraceuticals & Dietary Supplements, Vitamin Tablets & Capsules, TB, Tumor & Cancer Drugs, Anti Cancer Injection, Respiratory System Drugs, Anti Asthma Drug.
Who are the key members and board of directors at Brix Biopharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Atish Jain  | Managing Director | 14-Feb-2024 | Current |
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Dipesh Shah | Director | 14-Feb-2024 | Current |
| Kamlesh Jain | Director | 14-Feb-2024 | Current |
| Priyank Punmiya | Director | 15-Nov-2019 | Current |
| Najul Nagda | Director | 15-Nov-2019 | Current |
Financial Performance of Brix Biopharma.
Brix Biopharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 495.97% increase. The company also saw a substantial fall in profitability, with a 22.66% decrease in profit. The company's net worth Soared by an impressive increase of 80.41%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Brix Biopharma?
In 2022, Brix Biopharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Dheer Health Care Private LimitedActive 9 years 4 monthsKamlesh Jain and Atish Jain are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 28 Feb 2024 | ₹7.60 Cr | Open |
How Many Employees Work at Brix Biopharma?
Unlock and access historical data on people associated with Brix Biopharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Brix Biopharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Brix Biopharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
